Hear one clinical investigator’s data on a topical OAB medication that resulted in a significant reduction in urinary incontinence episodes associated with OAB – with a low rate of the side effects that can cause patients to discontinue oral treatments.1-3
In this Urology Times® on-demand podcast, Evan Goldfischer, MD, describes the findings of a phase III, double-blind, randomized, controlled trial of Gelnique 3%TM (oxybutynin) gel 3%, featuring a novel carrier molecule which delivers its active ingredient directly into the bloodstream.1
PODCAST: Dr. Goldfischer on OAB
Gelnique 3% is indicated for the treatment of overactive bladder with
symptoms of urge urinary incontinence, urgency, and frequency.
Important Safety Infomation
The most commonly reported adverse events associated with the use of Gelnique 3% included dry mouth (12.1%), application site erythema (3.7%), and application site rash (3.3%). Gelnique 3% is contraindicated in patients with urinary retention, gastric retention, or uncontrolled narrow-angle glaucoma, and in patients who are at risk for these conditions.Gelnique 3% should be used with caution in patients with clinically significant bladder outflow obstruction, myasthenia gravis, gastrointestinal obstructive disorders, ulcerative colitis, intestinal atony, gastroesophageal reflux and those concurrently taking drugs that can cause or exacerbate esophagitis. Angioedema requiring hospitalization and emergency medical treatment has occurred with the first or subsequent doses of oxybutynin pills. If angioedema occurs, Gelnique 3% should be discontinued and appropriate therapy promptly provided. Transference of oxybutynin to another person can occur when vigorous skin-to-skin contact is made with the application site. Patients should be instructed to avoid open flame or smoking until the gel has dried.
Please click here to see full Prescribing Information.
References: 1.Gelnique 3% (oxybutynin) Gelnique 3% [prescribing information]. Parsippany, NJ: Watson Pharma, Inc.; 2011. 2. Data on file. Watson Laboratories, Inc. 3. Basra RK, Wagg A, Chapple C, et al. A review of adherence to drug therapy in patients with overactive bladder. BJU Int. 2008;102(7):774-779.